Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases
| Autor: | Youlia M. Kirova, Catherine Delva, Bruno Cutuli, Julien Edeline, Hervé Mignotte, Yazid Belkacemi, Pascale Romestaing, Claire Lemanski, C. Cohen-Solal Le-Nir, B. De Lafontan, Z. Gaci, D. Serin, C. Tunon de Lara, Frédérique Penault-Llorca, M. Zoubir, B. Comet, P. Maingon |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Gastroenterology Breast Neoplasms Male Cohort Studies Young Adult Breast cancer Internal medicine medicine Humans Mastectomy Radical mastectomy Aged Aged 80 and over Gynecology Univariate analysis Aromatase Inhibitors business.industry Lumpectomy Cancer Hematology Middle Aged Prognosis medicine.disease Tamoxifen Oncology Male breast cancer T-stage business |
| Zdroj: | Critical Reviews in Oncology/Hematology. 73:246-254 |
| ISSN: | 1040-8428 |
| Popis: | Infiltrating MBC represents less than 1% of all male cancers. Our study details clinico-pathological features, treatments and prognostic factors in a large French cohort.Four hundred and eighty-nine patients were collected from 1990 to 2005. Median age was 66 years (34% over 70 years) and median follow-up 58 months.According to TN classification, we found T(1): 39%, T(2): 41%, T(3)T(4): 9%, T(x): 11% and N(1)N(2): 27%. Lumpectomy (L) and mastectomy (M) were performed in 8.6% and 91.4% of the cases. Axillary dissection (AD), sentinel node biopsy or both were performed in 90%, 2% and 5% of the cases, respectively. Ninety-five percent of tumours were ductal carcinomas; 47% were pT(1), 20% pT(2) and 33% pT(3)-T(4). Axillary nodal involvement was present in 52.8% cases. ER and PgR were positive in 92% and 89% cases. Radiotherapy (RT) was performed in 85% of the patients. Hormonal treatment (HT) was delivered in 72% of the cases. Tamoxifen and aromatase inhibitors were used in 85% and 12% of the cases; 34% of the patients received chemotherapy (CT). Local recurrence (LR), nodal recurrences (NR) and metastases occurred in 2%, 5% and 22% of the cases; 2% and 10% developed contralateral BC and second cancer. The 5- and 10-year overall survival (OS) rates were 81% and 59%; disease-specific survivals (DSS) were 89% and 72%. Death causes were BC 56%, second cancer 8%, complications 3%, intercurrent disease 15% and unknown 18%. In a univariate analysis, metastatic risk factors were T stage (T1: 19%, T(2): 26%, T(3)T(4): 40%; p=0.013), pN status (pN(0): 12% pN(1-3): 26% pN(3): 44%; p0.0001) and presence of locoregional recurrence (62% versus 18% p0.0001). In a multivariate analysis, axillary nodal involvement and high SBR remain prognostic factors.Earlier diagnosis and wide use of adjuvant treatments (RT/HT/CT) widely decreased LR and increased survival rates in MBC, reaching female ones. Prognostic factors were also very similar to female ones. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect